Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/121875
Title: | Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study |
Author: | Ibáñez Sanz, Gemma Díez Villanueva, Anna Vilorio-Marqués, Laura Gracia Lavedan, Esther Aragonès Sanz, Núria Olmedo Requena, Rocío Llorca Díaz, Javier Vidán, Juana Amiano, Pilar Nos, Pilar Fernández Tardón, Guillermo Rada, Ricardo Chirlaque, María Dolores Guinó, Elisabet Dávila Batista, Verónica Castaño-Vinyals, Gemma Pérez Gómez, Beatriz Mirón Pozo, Benito Dierssen Sotos, Trinidad Etxeberria, Jaione Molinuevo, Amaia Álvarez-Cuenllas, Begoña Kogevinas, Manolis Pollán, Marina Moreno Aguado, Víctor |
Keywords: | Espanya Càncer colorectal Estudi de casos Medicina preventiva Spain Colorectal cancer Case studies Preventive medicine |
Issue Date: | 1-Feb-2018 |
Publisher: | Nature Publishing Group |
Abstract: | A safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim to evaluate the association between the use of glucosamine and/or chondroitin sulphate and risk of colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic factors, lifestyle, family and medical history and regular drug use. Adjusted odds ratios and their 95% confidence intervals were estimated. The reported frequency of chondroitin and/or glucosamine use was 2.03% in controls and 0.89% in cases. Users had a reduced risk of CRC (OR: 0.47; 95% CI: 0.28-0.79), but it was no longer significant when adjusted for NSAID (nonsteroidal anti-inflammatory drugs) use (OR: 0.82; 95% CI: 0.47-1.40). A meta-analysis with previous studies suggested a protective effect, overall and stratified by NSAID use (OR: 0.77; 95% CI: 0.62-0.97). We have not found strong evidence of an independent preventive effect of CG on CRC in our population because the observed effects of our study could be attributed to NSAIDs concurrent use. These results merit further research due to the safety profile of these drugs. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/s41598-018-20349-6 |
It is part of: | Scientific Reports, 2018, vol. 8, num. 1, p. 2040 |
URI: | http://hdl.handle.net/2445/121875 |
Related resource: | https://doi.org/10.1038/s41598-018-20349-6 |
ISSN: | 2045-2322 |
Appears in Collections: | Articles publicats en revistes (ISGlobal) Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
679248.pdf | 918.27 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License